Navigation Links
2 carotid artery stenting studies show results comparable to AHA guidelines
Date:10/23/2007

Washington D.C., October 23, 2007 - Two carotid stenting trials examining patient outcomes demonstrated results that are comparable to guidelines established by the American Heart Association (AHA) for patients treated with carotid artery surgery. The results of these studies were presented today at the Cardiovascular Research Foundation's 19th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium by William A. Gray, M.D., FACC, associate professor of clinical medicine at Columbia University College of Physicians and Surgeons and director of Endovascular Services at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center in New York. Dr. Gray is the director of Endovascular Services at the Cardiovascular Research Foundation.

An interim analysis of patients treated with carotid stents in Abbotts CAPTURE 2 (Carotid ACCULINK/ACCUNET Post Approval Trial to Uncover Rare Events) and EXACT (Emboshield and Xact Post Approval Carotid Stent Trial) post-marketing trials, which enrolled 4,111 patients in over 150 sites, demonstrated 30 day patient outcome results consistent with longstanding AHA guidelines for patients with a severe carotid stenosis but who do not have symptoms. These guidelines recommend that rates of complications for carotid artery surgery to prevent stroke be less than 3 percent for patients without symptoms of stroke (asymptomatic) and 6 percent for patients with symptoms of stroke (symptomatic).

In these two well-conducted carotid artery stenting studies, carotid stenting has achieved outcomes comparable guidelines established for patients who undergo carotid surgery, and has done so in a population of patients who are at high risk for experiencing adverse events from surgery, said Dr. Gray. This is a significant report because this is the first time that these guidelines have been achieved by any revascularization therapy in a large, multi-center examination of such patients, and although the guidelines were established for surgery (before stenting was practiced), there are no comparable surgical results in this group of patients.

In 1998, the American Heart Association published its 30 day outcome guidelines in Circulation for patients treated with carotid artery surgery. These guidelines were based on the observed stroke and death rates in patients with carotid artery disease who had undergone surgery, called carotid endarterectomy, to treat their condition. The guidelines were based on studies of surgery in patients who did not have excessive risks for anesthesia, etc., but left unanswered what the best therapy is for patients for whom surgery was risky. These two studies are the first demonstration of a therapy providing stroke prevention (carotid artery stenting) in these patients and they provide an option to those facing difficult decisions regarding the risks of surgery.

The CAPTURE 2 study included 1,987 patients and utilized Abbott's ACCULINK(tm) Carotid Stent System and ACCUNET(tm) Embolic Protection System. The EXACT study included 2,124 patients and utilized Abbott's Xact(r) Rapid Exchange Carotid Stent System and Emboshield BareWire(tm) Rapid Exchange Embolic Protection System. The key objective of both trials was to determine whether carotid stenting could be performed safely in the real-world clinical setting by physicians with varying levels of experience. The primary endpoints were death, stroke and MI at 30 days. The demographics of patients in both trials were similar.

The 30-day composite endpoints of stroke and death for patients in the CAPTURE 2 and EXACT studies were:

  • 3.1 percent and 3.0 percent combined stroke and death in CAPTURE 2 and EXACT patients without symptoms under age 80
  • 6.0 percent and 7.3 percent combined stroke and death in CAPTURE 2 and EXACT patients with symptoms under age 80
  • 3.8 percent and 4.0 percent stroke and death within 30-days of treatment for the combined patient populations


'/>"/>

Contact: Alex Lyda
mal2133@columbia.edu
917-755-0354
Columbia University Medical Center
Source:Eurekalert

Related biology news :

1. Columbia study shows widely used artery clearing device does not help patients during heart attack
2. Measuring artery repair cells could become new heart disease test
3. Studies reveal methods viruses use to sidestep immune system
4. New studies suggest airborne SARS transmission is possible
5. Studies reveal how plague disables immune system, and how to exploit the process to make a vaccine
6. Two studies document rise of superbugs in the environment
7. UI researcher studies deafness in fruit flies, humans
8. Biased reporting found in cancer prognostic studies
9. Fruit fly studies open new window on cancer research
10. Why do aneurysms form? New studies suggest leading role for white blood cells
11. Studies clarify risk factors for mother-to-child transmission of hepatitis C virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... the trading session at 4,833.32, down 0.22%; the Dow Jones ... the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ... BIND Therapeutics Inc. (NASDAQ: BIND ). Learn more ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, ... tools designed, tuned and optimized exclusively for Okuma CNC machining centers at The ... of a collaboration among several companies with expertise in toolholding, cutting tools, machining ...
(Date:6/22/2016)... , June 22, 2016 Cell ... will allow them to produce up to one ... one lot within one week. These high-quality, consistent ... laboriously preparing cells and spend more time doing ... through a proprietary, high-volume manufacturing process that produces ...
Breaking Biology Technology: